ArticleJournal of oncology practice2019
2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.
Article in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- The impact of early oral anticancer medication monitoring through electronic patient assessments.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Trial
- Implementation and Resource Optimization of an Oral Anticancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre.Current oncology (Toronto, Ont.) · 2026Article
- Community pharmacists are not yet ready to manage oral anti-cancer agents: beyond safe dispensing and basic education.The International journal of pharmacy practice · 2026Article
- Evaluating large language models for pharmacotherapy simulations: a mixed-methods study.NPJ digital medicine · 2026Article
- A Short Patient-Reported Outcome Measure for Oral Anticancer Agents: Multicenter Observational Study.JMIR formative research · 2026Observational
- Capacity, motivation, and opportunity model-derived taxonomy of pharmacist-led interventions applicable to people self-managing cancer medication.Frontiers in public health · 2026Article
- Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning.Pharmacy (Basel, Switzerland) · 2025Review
- Assessment of Standards of Care for Oral Chemotherapy by Pharmacists in Clinical Settings.Journal of the advanced practitioner in oncology · 2025Article
- Design and implementation of a risk-adapted, longitudinal, theory-driven medication adherence intervention: A protocol for a multi-phasic, hybrid effectiveness-implementation trial.Research in social & administrative pharmacy : RSAP · 2025Article
- Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists' Perspectives.Journal of the advanced practitioner in oncology · 2025Review
- Implementation of an Improvement Cycle in the Compounding of Antineoplastic Therapy in a University Hospital.Health care science · 2025Article
- Optimizing Adherence to Oral Anticancer Agents: Results from an Implementation Mapping Study.Current oncology (Toronto, Ont.) · 2025Article
- Pharmacist-facilitated Patient Reported Outcome Measure (PROM) monitoring: developing an EHR SmartForm© to monitor side effects of oral oncolytics during routine telehealth encounters.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Effectiveness of pharmacist-managed oncology ambulatory care for patients with non-small cell lung cancer in Taiwan.Journal of food and drug analysis · 2024Article
- Impact of VA Hematology/Oncology Clinical Pharmacy Practitioners in the Review of Community Prescriptions for Specialty Medications.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Clinical Pharmacist-Led Interventions for Improving Breast Cancer Management-A Scoping Review.Current oncology (Toronto, Ont.) · 2024Article
- Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2024Article
- Managing Drug Interactions With Oral Anticancer Treatments.Journal of the advanced practitioner in oncology · 2023Article
- Article
- Cardiometabolic Consequences of Targeted Anticancer Therapies.Journal of cardiovascular pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the current work was to present a pharmacy practice standard from the Hematology/Oncology Pharmacy Association (HOPA) on the management of oral oncolytic therapy.
methodsThe HOPA Standards Committee organized a work group of oncology pharmacist specialists to create a pharmacy practice standard for the management of oral oncolytic therapy that describes the pharmacist's role on the cancer care team, provides examples of practice tools and resources, summarizes current data related to outcomes, and discusses opportunities to enhance the care of patients with cancer who receive oral oncolytic therapy. We reviewed primary literature, including currently published oral oncolytic guidelines and HOPA's Scope of Hematology/Oncology Pharmacy Practice.
resultsManagement of oral oncolytic therapy was divided into the following primary areas: prescribing, education, dispensing and distribution, and monitoring and follow-up. Pharmacists' roles were summarized in each area with a focus on interprofessional collaboration, communication, patient safety, and quality of patient care. Standards describe the best practices in each area ( Table 1 ).
conclusionMultiple opportunities exist for pharmacists to enhance the care of patients with cancer who receive oral oncolytics through collaboration with oncology care team members. The role of the oncology pharmacist in the care of this patient population is critical given the complexities related to cost, tolerability, and safety of oral oncolytic medications; issues of access; and the monitoring and follow-up of patients receiving this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.